Recent Updates
Recently added Catalysts

ASP1517

Phase 1

Healthy Subjects | Small molecule | Other |Kyntra Bio, Inc.|Last Updated: Jan 25, 2017

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedCONTROLLEDBiomarker
Total Trials2
Total Enrollment34
FDA Designations
No designations recorded
Clinical Trials (2)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT02952040A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP1517 and Lanthanum Carbonate HydratePHASE1 COMPLETED 18Nov 1, 2016Dec 1, 2016Jan 25, 20171 Japan
NCT02805374A Food Effect Study to Evaluate the Pharmacokinetics of ASP1517PHASE1 COMPLETED 16Jul 1, 2016Aug 1, 2016Aug 24, 20161 Japan
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Pharmacokinetics (PK) parameter of ASP1517 in plasma: AUCINF
Up to 72hr after each dosing

AUCinf: Area under the concentration-time curve from the time of dosing extrapolated to time infinity

PK parameter of ASP1517 in plasma: AUC24h
Up to 72hr after each dosing

AUC24h: Area under the concentration-time curve from the time of dosing to 24h

PK parameter of ASP1517 in plasma: Cmax
Up to 72hr after each dosing

Cmax: Maximum concentration

Secondary Endpoints
PK parameter of ASP1517 in plasma: AUClast
Up to 72hr after each dosing
PK parameter of ASP1517 in plasma: CL/F
Up to 72hr after each dosing
PK parameter of ASP1517 in plasma: t1/2
Up to 72hr after each dosing
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposeBASIC_SCIENCE
Treatment Arms
ArmTypeDescription
ASP1517 alone period preceding groupEXPERIMENTALSubjects will receive a single oral dose of ASP1517 alone in period 1, then subjects will receive a single oral dose of ASP1517 with lanthanum carbonate hydrate in period 2.
ASP1517+lanthanum period preceding groupEXPERIMENTALSubjects will receive a single oral dose of ASP1517 with lanthanum carbonate hydrate in period 1, then subjects will receive a single oral dose of ASP1517 alone in period 2.
ASP1517 fasting then fedEXPERIMENTALSubjects will receive a single oral dose of ASP1517 under fasting conditions in period 1, then subjects will receive a single oral dose of ASP1517 under fed conditions in period 2.
ASP1517 fed then fastingEXPERIMENTALSubjects will receive a single oral dose of ASP1517 under fed conditions in period 1, then subjects will receive a single oral dose of ASP1517 under fasting conditions in period 2.
Interventions
NameTypeDescription
ASP1517DRUGOral dose
Lanthanum carbonate hydrateDRUGOral dose
Unlock Study Design Details
Eligibility Criteria
Age Range20 Years — 44 Years
SexMALE
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Body weight (at screening): ≥50.0 kg and \<80.0 kg * Body-mass index (at screening): ≥17.6 and \<26.4 kg/m2 \[Body-mass index = Body weight (kg)/(Height (m))2\] * Subject must agree to use contraception consisting of two established forms specified below starting at the time o...

Countries:Japan
Unlock Eligibility Criteria